SEC Comment Letter 0000000000-23-013343 to TENAX THERAPEUTICS, INC. (TENX)
TENAX THERAPEUTICS, INC.
Date: Dec. 7, 2023 · CIK: 0000034956 · Accession: 0000000000-23-013343
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-275856
Letter
United States securities and exchange commission logo December 7, 2023 Christopher T. Giordano President and Chief Executive Officer Tenax Therapeutics, Inc. 101 Glen Lennox Drive, Suite 300 Chapel Hill, NC 27517 Re:Tenax Therapeutics, Inc. Registration Statement on Form S-1 Filed December 1, 2023 File No. 333-275856 Dear Christopher T. Giordano: We have conducted a limited review of your registration statement and have the following comment. Please respond to this letter by amending your registration statement and providing the requested information. If you do not believe a comment applies to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in your response. After reviewing any amendment to your registration statement and the information you provide in response to this letter, we may have additional comments. Registration Statement on Form S-1 filed December 1, 2023 Coverpage 1.Please revise your cover page to disclose the date the offering will end. Refer to Item 501(b)(8)(iii) of Regulation S-K for guidance. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Refer to Rules 460 and 461 regarding requests for acceleration. Please allow adequate time for us to review any amendment prior to the requested effective date of the registration statement. Please contact Daniel Crawford at 202-551-7767 or Jason Drory at 202-551-8342 with any other questions.
FirstName LastNameChristopher T. Giordano Comapany NameTenax Therapeutics, Inc. December 7, 2023 Page 2 FirstName LastName Christopher T. Giordano Tenax Therapeutics, Inc. December 7, 2023 Page 2 Sincerely, Division of Corporation Finance Office of Life Sciences cc: Lorna Knick, Esq.
Show Raw Text
United States securities and exchange commission logo
December 7, 2023
Christopher T. Giordano
President and Chief Executive Officer
Tenax Therapeutics, Inc.
101 Glen Lennox Drive, Suite 300
Chapel Hill, NC 27517
Re:Tenax Therapeutics, Inc.
Registration Statement on Form S-1
Filed December 1, 2023
File No. 333-275856
Dear Christopher T. Giordano:
We have conducted a limited review of your registration statement and have the
following comment.
Please respond to this letter by amending your registration statement and providing the
requested information. If you do not believe a comment applies to your facts and circumstances
or do not believe an amendment is appropriate, please tell us why in your response.
After reviewing any amendment to your registration statement and the information you
provide in response to this letter, we may have additional comments.
Registration Statement on Form S-1 filed December 1, 2023
Coverpage
1.Please revise your cover page to disclose the date the offering will end. Refer to Item
501(b)(8)(iii) of Regulation S-K for guidance.
We remind you that the company and its management are responsible for the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action or absence of
action by the staff.
Refer to Rules 460 and 461 regarding requests for acceleration. Please allow adequate
time for us to review any amendment prior to the requested effective date of the registration
statement.
Please contact Daniel Crawford at 202-551-7767 or Jason Drory at 202-551-8342 with
any other questions.
FirstName LastNameChristopher T. Giordano
Comapany NameTenax Therapeutics, Inc.
December 7, 2023 Page 2
FirstName LastName
Christopher T. Giordano
Tenax Therapeutics, Inc.
December 7, 2023
Page 2
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Lorna Knick, Esq.